Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Equol is a metabolite of the soy isoflavone daidzein, produced by intestinal bacteria in some individuals after soy consumption. It has garnered scientific interest due to its estrogenic activity, which is thought to be relevant in the context of osteoporosis—a condition often associated with decreased estrogen levels, particularly in postmenopausal women. Several clinical and preclinical studies suggest that equol, especially S-equol (the enantiomer produced in humans), can bind to estrogen receptor beta with high affinity, potentially mimicking some of the bone-protective effects of endogenous estrogens.

Randomized controlled trials and observational studies have indicated that individuals capable of producing equol from dietary soy may experience greater bone-sparing benefits compared to non-producers. Some studies using proprietary S-equol supplements (such as SE5-OH) in postmenopausal women have shown modest improvements in markers of bone turnover and, in some cases, bone mineral density. However, the magnitude of these effects is generally moderate, and not all studies have observed significant clinical outcomes, especially over the short term.

Overall, while there is a scientific rationale and preliminary human research supporting the use of equol for osteoporosis, the body of evidence is not yet robust or consistent enough to warrant a higher evidence score. Larger, longer-term trials are needed to fully establish its efficacy and safety for osteoporosis prevention or treatment.

More about Equol (proprietary)
More about Osteoporosis

Other ingredients used for Osteoporosis

Other health conditions supported by Equol (proprietary)

Products containing Equol (proprietary)

Nature's Sunshine Equolibrium™